Specific endothelin-A receptor antagonism for the treatment of advanced prostate cancer

BJU Int. 2009 Nov;104(10):1423-5. doi: 10.1111/j.1464-410X.2009.08740.x. Epub 2009 Jul 14.

Authors

Karim Fizazi¹, Kurt Miller

Affiliation

¹ Institut Gustave Roussy, University of Paris XI, Villejuif, France, and Charité, Universitätsmedizin Berlin, Berlin, Germany. [email protected]

PMID: 19624592
DOI: 10.1111/j.1464-410X.2009.08740.x

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Clinical Trials, Phase III as Topic
Endothelin A Receptor Antagonists*
Humans
Male
Prostatic Neoplasms / drug therapy*
Pyrrolidines / therapeutic use*
Randomized Controlled Trials as Topic

Substances

Endothelin A Receptor Antagonists
Pyrrolidines
ZD4054